£10m up for grabs to fight against antimicrobial resistance; but is it too little?
This article was originally published in Clinica
The swell of voices calling for action against antimicrobial resistance (AMR) is growing louder. In June 2013, the G8 science ministers meeting identified AMR as humanity’s most pressing concern, while the World Health Organization put out a report in April that revealed how our last line of defences against resistant bacteria is crumbling.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.